Akero Therapeutics, Inc.
AKRO
$48.31
$0.280.58%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 0.31% | -1.00% | 3.69% | -29.86% | -4.95% |
Total Depreciation and Amortization | -- | -- | 1,400.00% | 0.00% | 0.00% |
Total Amortization of Deferred Charges | 4.49% | 2.30% | 6.10% | 4.46% | 40.18% |
Total Other Non-Cash Items | -1.48% | 56.97% | 5.46% | -25.48% | 4.86% |
Change in Net Operating Assets | 534.83% | -159.61% | 23.00% | 73.79% | -152.65% |
Cash from Operations | 28.70% | -0.86% | 4.73% | -22.58% | -63.50% |
Capital Expenditure | -- | -- | -- | 100.00% | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 116.45% | -3,257.30% | -79.10% | 128.67% | -540.62% |
Cash from Investing | 116.45% | -3,257.30% | -79.10% | 128.55% | -542.35% |
Total Debt Issued | -- | -- | -- | -- | -100.00% |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.13% | 421.06% | 2,327.98% | 857.49% | -99.91% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 100.00% | -1,886.21% | 54.69% | 86.58% | -74.09% |
Cash from Financing | -99.13% | 420.50% | 2,377.70% | 2,144.67% | -100.04% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 122.37% | -738.38% | 323.35% | 101.82% | -180.46% |